Haemonetics Co. (NYSE:HAE) Shares Purchased by Northern Trust Corp

Northern Trust Corp increased its position in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 16.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 678,261 shares of the medical instruments supplier's stock after purchasing an additional 93,848 shares during the period. Northern Trust Corp owned 1.35% of Haemonetics worth $52,959,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Nordea Investment Management AB boosted its holdings in shares of Haemonetics by 5.5% during the 4th quarter. Nordea Investment Management AB now owns 104,175 shares of the medical instruments supplier's stock valued at $8,152,000 after purchasing an additional 5,385 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in Haemonetics during the fourth quarter valued at approximately $402,000. KBC Group NV grew its holdings in Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after buying an additional 712 shares in the last quarter. Pacer Advisors Inc. increased its stake in Haemonetics by 36.1% in the 4th quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock worth $789,000 after acquiring an additional 2,680 shares during the last quarter. Finally, Boston Trust Walden Corp raised its holdings in shares of Haemonetics by 13.1% during the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock worth $71,500,000 after acquiring an additional 106,114 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Stock Up 0.3 %

Shares of NYSE HAE traded up $0.20 during mid-day trading on Friday, reaching $68.21. 782,442 shares of the company were exchanged, compared to its average volume of 694,988. The firm has a 50-day moving average of $62.75 and a 200 day moving average of $71.39. Haemonetics Co. has a 1 year low of $55.30 and a 1 year high of $97.97. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The stock has a market cap of $3.43 billion, a price-to-earnings ratio of 26.85, a P/E/G ratio of 1.11 and a beta of 0.32.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. The business had revenue of $330.60 million for the quarter, compared to analysts' expectations of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The company's revenue was down 3.5% compared to the same quarter last year. During the same period last year, the business earned $0.90 EPS. On average, research analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Barrington Research reduced their price target on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. JMP Securities decreased their target price on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research report on Friday, February 7th. Needham & Company LLC decreased their price objective on Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Thursday. Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and lowered their price target for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Finally, Raymond James restated a "strong-buy" rating and issued a $105.00 target price (down previously from $115.00) on shares of Haemonetics in a report on Friday. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Haemonetics has an average rating of "Moderate Buy" and a consensus target price of $97.89.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.